Topic: Endochrine Disorders | Hospital Pharmacy Europe
This site is intended for health professionals only
Tuesday 21 August 2018
Share |

Topic: Endochrine Disorders

February 26, 2018
Crysvita acknowledged by European Medicines Agency as an outstanding contribution to public health

Kyowa Hakko Kirin, Kyowa Kirin International and Ultragenyx have announced that Crysvita (burosumab) has received a positive European Commission decision granting a conditional marketing authorisation to Kyowa Kirin for the treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons.

 

XLH is a rare, chronic progressive musculoskeletal disorder that affects children and adults.

 

July 25, 2017
Novel compound belongs to an emerging form of treatments called peptide receptor radionuclide therapy, which involves targeting tumours with radiolabelled molecules that bind to specific receptors expressed by the tumour

Advanced Accelerator Applications S.A has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the marketing authorisation of lutetium (177Lu) oxodotreotide (Lutathera®) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.
 

March 11, 2015
New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.

New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.
 

 

January 20, 2015
Moderate chronic kidney disease affects up to 40% of all people with type 2 diabetes in the UK, which is approximately one million people (1,2). Type 2 diabetes costs the NHS a total of £21.8 billion in 2010/2011, with the complications of chronic kidney disease accounting for an estimated £753.8 million. These figures are predicted to rise to £35.6 billion for type 2 diabetes and £1.3 billion for kidney disease in people with type 2 diabetes by 2035/36 (3). The licence extension for Victoza® (liraglutide) increases clinicians’ prescribing options to help patients with both conditions achieve glucose control.
  • Moderate chronic kidney disease affects up to 40% of all people with type 2 diabetes in the UK, which is approximately one million people (1,2).
  • Type 2 diabetes costs the NHS a total of £21.8 billion in 2010/2011, with the complications of chronic kidney disease accounting for an estimated £753.8 million. These figures are predicted to rise to £35.6 billion for type 2 diabetes and £1.3 billion for kidney disease in people with type 2 diabetes by 2035/36 (3).
December 19, 2014
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged 1–17 years with diabetes. Once the European Commission approves the licence extension, physicians in the European Union will be able to prescribe insulin degludec to children and adolescents aged 1–17 with type 1 and type 2 diabetes.

Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged 1–17 years with diabetes. Once the European Commission approves the licence extension, physicians in the European Union will be able to prescribe insulin degludec to children and adolescents aged 1–17 with type 1 and type 2 diabetes.

March 25, 2014
Boehringer Ingelheim and Eli Lilly and Company are pleased to announce a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommending approval of the investigational sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin* (if approved to be marketed under the name Jardiance®) for the treatment of adults with Type 2 Diabetes (T2D).

 

March 24, 2014
Boehringer Ingelheim and Eli Lilly and Company have announced results from an online poll of more than 700 physicians treating people with Type 2 Diabetes (T2D) from across six Latin American countries: Argentina, Brazil, Columbia, Mexico, Panama and Venezuela.

 

September 25, 2013
Takeda Pharmaceutical Company Limited (Takeda) has announced that the European Commission has granted Marketing Authorization (MA) for Vipidia(™)(alogliptin), a dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of type 2 diabetes patients who are uncontrolled on existing therapies[1-3] and for the fixed-dose combination (FDC) therapies Vipdomet(™) (alogliptin with metformin) and IncresyncTM (alogliptin with pioglitazone). The Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), issued a positive opinion for these products on July 26, 2013.

 

June 4, 2013
Biopartners GmbH, a wholly owned subsidiary of Bioton SA, Poland, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion regarding the approval of once-weekly Somatropin Biopartners for the treatment of growth hormone deficiency (GHD) in paediatric and adult patients.

teaser

June 4, 2013
The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) for Bristol-Myers Squibb and AstraZeneca

teaser

May 28, 2013
Results of the INTERVAL study were published online in The Lancet today and for the first time demonstrated the feasibility of setting and achieving individualised treatment targets in elderly patients with type 2 diabetes.

teaser

May 28, 2013
Boehringer Ingelheim and Eli Lilly & Company have launched an educational digital game for type 2 diabetes called Complications Combat.

teaser

May 24, 2013
Takeda

teaser

February 8, 2013
The Forum for Injection Technique (FIT) announce the launch of FIT in Ireland, and the First Irish Injection Technique Recommendations in diabetes.

teaser

November 14, 2012
Today (14th Nov) sees the culmination of week-long activities at Boehringer Ingelheim aiming to raise awareness of the global diabetes epidemic, in support of World Diabetes Day.

teaser

November 8, 2012
The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor

teaser

October 29, 2012
Boehringer Ingelheim and Eli Lilly and Company have announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta

teaser

October 4, 2012
New data presented today at the Annual Meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes starting insulin therapy had a 43% lower rate of night-time hypoglycaemia* when using insulin degludec compared with those using insulin glargine (0.27 [insulin degludec] versus 0.46 [insulin glargine] episodes per patient per year, p<0.001) with equivalent improvements in glucose control.**(1)

teaser

October 3, 2012
Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes.

teaser

October 3, 2012
Novartis announced today new data showing that a significantly higher proportion of type 2 diabetes patients responded to treatment with either Galvus

teaser

September 25, 2012
Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a Positive Opinion from the European Medicines Agency

teaser

September 21, 2012
Novartis announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued two positive opinions for new indications for the use of Galvus

teaser

September 20, 2012
WISE (Workshop on Injection Safety in Endocrinology) has published new global recommendations on ensuring the safety of injections in diabetes.

teaser

July 24, 2012
EMA Committee for Orphan Medicinal Products issued positive opinion for hepatology candidate A4250

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine